Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+353-1-6096000
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees23,044
OptionableNot Optionable
Shire (LON:SHP) Frequently Asked Questions
What is Shire's stock symbol?
Shire trades on the London Stock Exchange (LON) under the ticker symbol "SHP."
How often does Shire pay dividends? What is the dividend yield for Shire?
Shire declared a dividend on Tuesday, July 31st. Shareholders of record on Thursday, September 6th will be given a dividend of GBX 4.26 per share on Friday, October 19th. This represents a yield of 0.1%. The ex-dividend date of this dividend is Thursday, September 6th. The official announcement can be seen at this link. View Shire's Dividend History.
What price target have analysts set for SHP?
22 analysts have issued 1-year price objectives for Shire's stock. Their predictions range from GBX 3,600 to GBX 8,000. On average, they anticipate Shire's stock price to reach GBX 4,771.80 in the next year. This suggests a possible upside of 1.7% from the stock's current price. View Analyst Price Targets for Shire.
What is the consensus analysts' recommendation for Shire?
22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shire in the last year. There are currently 7 hold ratings, 14 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Shire.
Has Shire been receiving favorable news coverage?
Press coverage about SHP stock has been trending positive recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Shire earned a news sentiment score of 2.7 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
Who are some of Shire's key competitors?
Some companies that are related to Shire include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Actinogen Medical (ACW), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE) and Ampliphi Biosciences (APHB).
Who are Shire's key executives?
Shire's management team includes the folowing people:
- Dr. Flemming Ornskov M.P.H., MBA, M.D., MPH, CEO, MD & Exec. Director (Age 60)
- Mr. Thomas J. W. Dittrich, CFO & Director (Age 54)
- Gisele Dion, Chief Accounting Officer
- Mr. Matthew Walker, Head of Technical Operations (Age 54)
- Dr. Andreas Busch Ph.D., Head of R&D and Chief Scientific Officer (Age 55)
How do I buy shares of Shire?
Shares of SHP and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Shire's stock price today?
One share of SHP stock can currently be purchased for approximately GBX 4,690.
What is Shire's official website?
How can I contact Shire?
Shire's mailing address is Miesian Plaza 50-58 Baggot Street Lower, Block 2, DUBLIN, D02 HW68, Ireland. The biopharmaceutical company can be reached via phone at +353-1-6096000.
MarketBeat Community Rating for Shire (LON SHP)
MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe SHP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SHP will underperform the S&P 500 over the long term. You may vote once every thirty days.
